Get the Daily Brief
Latest Biotech News
SMART Alliance Unveils Automated RNA Modification Tool for Cancer Research
Scientists from the Singapore-MIT Alliance for Research and Technology (SMART) have developed the first automated high-throughput platform to analyze transfer RNA (tRNA) chemical modifications...
Novartis-Arrowhead Parkinson’s RNAi Deal – $200M Upfront
Novartis has licensed a preclinical RNA interference (RNAi) therapy from Arrowhead Pharmaceuticals targeting alpha-synuclein, a protein implicated in Parkinson's disease and other...
Ionis’ Olezarsen Phase 3 Triumph – Severe Hypertriglyceridemia Benefits
Ionis Pharmaceuticals reported positive Phase 3 results for olezarsen in patients with severe hypertriglyceridemia (sHTG). The antisense oligonucleotide significantly reduced fasting triglycerides...
Amgen Commits $600M to New R&D Center in California
Amgen announced a $600 million investment to establish a state-of-the-art research and development center at its Thousand Oaks headquarters. The facility will foster interdisciplinary...
Eli Lilly’s Orforglipron Hits Phase 3 Weight Loss and Diabetes Targets
Eli Lilly announced that orforglipron, a once-daily oral GLP-1 receptor agonist, met primary and key secondary endpoints in the Phase 3 ATTAIN-2 trial involving adults with obesity or overweight...
Monod Bio Secures $1.5M Gates Grant for Urine TB Diagnostic
University of Washington spinout Monod Bio was awarded a $1.5 million grant from the Gates Foundation to develop a rapid urinary diagnostic test for tuberculosis suitable for low-resource...
Crunch Protein Redirects Phagocytosis to Eliminate Harmful Cells
Researchers at Kyoto University’s iCeMS introduced a synthetic protein therapeutic named Crunch that reprograms the body's natural cell clearance process to target and engulf living harmful cells,...
Mercy BioAnalytics Closes $59M Series B for Early Cancer Detection
Mercy BioAnalytics raised $59 million in Series B funding led by Novalis and Sozo Ventures to advance commercialization of its extracellular vesicle-based blood tests for early ovarian and lung...
AI Model Predicts Anticoagulation Needs in Atrial Fibrillation
Researchers at Mount Sinai developed a graph neural network-based artificial intelligence model to better determine which atrial fibrillation patients require blood thinners to prevent stroke. By...
Biochar’s Role in Agriculture and Climate Change Mitigation
Recent studies have examined biochar's potential as a negative emission technology to improve soil health and crop yields while reducing greenhouse gas emissions. Research published in 'Discover...
Editas Medicine Advances Gene Editing for High Cholesterol
Editas Medicine revealed EDIT-401 as its lead in vivo development candidate, an innovative gene editing therapy designed to reduce LDL cholesterol by increasing LDL receptor expression through...
ViCentra Raises $85M to Scale Insulin Patch Pump and US Market Entry
ViCentra secured $85 million in Series D funding led by Innovation Industries to accelerate manufacturing expansion and launch of its next-generation Kaleido 2 patch pump for insulin delivery. The...
Kyoto University Develops Protein Tool to Target Harmful Cells via Phagocytosis
Scientists at Kyoto University's iCeMS unveiled 'Crunch,' a synthetic protein that reprograms the body's phagocytes to selectively remove harmful living cells such as cancerous or overactive...
Novartis Invests $200M Upfront in Arrowhead’s RNAi Therapy Targeting Parkinson’s
Novartis forged a licensing agreement with Arrowhead Pharmaceuticals to develop ARO-SNCA, an RNA interference-based therapy targeting alpha-synuclein implicated in Parkinson's disease. The deal,...
Ionis Pharmaceuticals Expands Use of Oleazarsen After Positive Phase 3 for Hypertriglyceridemia
Ionis Pharmaceuticals announced favorable Phase 3 results for oleazarsen, its antisense oligonucleotide drug that significantly reduced triglyceride levels by up to 72% and decreased acute...
Eli Lilly’s Oral GLP-1 Orforglipron Shows Strong Weight Loss in Phase 3 Trial
Eli Lilly reported positive Phase 3 ATTAIN-2 trial results for orforglipron, an oral small molecule GLP-1 receptor agonist for obesity and type 2 diabetes. The highest dose yielded an average...
Medtech Partnerships Automate Nucleic Acid Quantification Workflows
Beckman Coulter Life Sciences and Hombrechtikon Systems Engineering (HSE) announced a strategic collaboration to automate nucleic acid quantification through integration of HSE photometer and...
Oxford Nanopore Revenues Rise 26% Driven by Clinical and Instrument Sales Growth
Oxford Nanopore Technologies reported a 26% year-over-year revenue increase for the first half of 2025, reaching £105.6 million ($141.3 million). Drivers include a 53% increase in instrument sales...
MedTech Giant Amgen Invests $600M to Expand California R&D Headquarters
Amgen announced a $600 million investment to expand its research and development site in Thousand Oaks, California. The state-of-the-art facility will focus on accelerating next-generation drug...
Moderna’s Spikevax LP.8.1 COVID-19 Vaccine Gains Approval in South Korea
South Korea’s Ministry of Food and Drug Safety approved Moderna’s updated Spikevax LP.8.1 vaccine targeting the LP.8.1 variant of SARS-CoV-2. This regulatory clearance follows the US FDA’s...